Abstract 58P
Background
Chimeric Antigen Receptor T-cell (CAR-T) therapies have revolutionized the treatment of certain hematologic malignancies. Despite their efficacy, these therapies are associated with significant adverse effects, including cardiotoxicity. Understanding the incidence, risk factors, and management strategies for CAR-T therapy-related cardiotoxicity is crucial for optimizing patient outcomes and improving safety profiles.
Methods
A systematic review and meta-analysis were conducted by searching PubMed, Embase, and Cochrane databases for studies published up to June 2024 that reported on cardiovascular outcomes in patients undergoing CAR-T therapy. Inclusion criteria were studies that provided detailed information on the incidence of cardiotoxic events, associated risk factors, and management strategies. Data were extracted independently by two reviewers and pooled using random-effects models to account for heterogeneity among studies. Subgroup analyses were performed to identify specific risk factors and effective management approaches.
Results
A total of 25 studies comprising 3,500 patients were included in the meta-analysis. The pooled incidence of cardiotoxic events among CAR-T therapy recipients was 18% (95% CI: 12%-25%). The most common cardiovascular complications were heart failure (10%), arrhythmias (6%), and myocardial infarction (2%). Risk factors significantly associated with increased cardiotoxicity included pre-existing cardiovascular disease (OR: 3.5, 95% CI: 2.1-5.8), older age (OR: 2.0, 95% CI: 1.3-3.2), and higher doses of CAR-T cells (OR: 1.8, 95% CI: 1.1-3.0). Effective management strategies identified included the use of beta-blockers, ACE inhibitors, and careful monitoring of cardiac function throughout the treatment course.
Conclusions
CAR-T cell therapies, while highly effective for treating hematologic malignancies, present a significant risk of cardiotoxicity. This meta-analysis highlights the importance of identifying high-risk patients and implementing proactive management strategies to mitigate these risks. Future research should focus on refining CAR-T protocols to minimize cardiotoxic effects and improve patient outcomes.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
21P - Impact of TP53 mutation subtypes on the efficacy of anti-PD-(L)1 immunotherapy in patients with non-small cell lung cancer
Presenter: Lige Wu
Session: Poster Display session
22P - Extracellular vesicles as predictive biomarkers for chemoimmunotherapy in biliary tract cancer
Presenter: Michele Zanoni
Session: Poster Display session
23P - Non-small cell lung cancer DNA methylation profiles correlate with immune checkpoint inhibitor response
Presenter: Julia Berger
Session: Poster Display session
24P - Blood DNA methylation profiles in NSCLC patients treated with immune checkpoint inhibitors
Presenter: Markus Kleinberger
Session: Poster Display session
25P - Circulating tumor DNA is predictive of overall survival in patients with metastatic uveal melanoma
Presenter: Egle Ramelyte
Session: Poster Display session
26P - Liquid biopsy-based percision immunotherapy: CCAT1 and HEIH lncRNAs identify young breast cancer patients likely to respond to PD-L1 blockade
Presenter: Rana Youness
Session: Poster Display session
27P - Single cell RNA sequencing (scRNAseq) analysis of peripheral immune cell populations from patients treated with anti-PD1 with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
Presenter: Séverine Carlier
Session: Poster Display session
28P - Circulating biomarkers in non-small cell lung cancer patients treated with immune checkpoint inhibitors
Presenter: Paola Ulivi
Session: Poster Display session
29P - Prognostic value of systemic inflammatory index and platelet-to-lymphocyte ratio in muscle-invasive bladder cancer patients treated with neoadjuvant chemo-immunotherapy in the AURA trial
Presenter: Jeremy Blanc
Session: Poster Display session
30P - The prognostic value of low density neutrophils in breast cancer: Implications for therapeutic strategies
Presenter: Telma Martins
Session: Poster Display session